Close Menu

microdroplet-based PCR

NEW YORK (GenomeWeb News) – Myriad Genetics will adopt RainDance Technologies' microdroplet PCR-based target enrichment technology for use in a next-generation sequencing-based hereditary cancer panel test that Myriad is currently developing, the companies said today.

NEW YORK (GenomeWeb News) – RainDance Technologies today said that it has completed a collaboration with MLL Munich Leukemia Laboratory on the development of a panel for use in the sequence-based analysis of acute myeloid leukemia and myelodysplastic syndromes.

SUNY researchers are developing a droplet microfluidics device to extract mRNA from single cells, creating cDNA libraries in individual droplets for gene expression analysis.

RainDance's Sequence Enrichment application enhances SeqWright's targeted resequencing and whole-genome sequencing capabilities for studying disease pathways, cancer, and other areas of research, SeqWright said.

Ambry Genetics, which has a CAP-accredited and CLIA-certified laboratory, is using RainDance's RDT 1000 for micro-droplet PCR-based enrichment of target DNA for sequencing.

Under the partnership, Ambry will incorporate RainDance's RDT 1000 platform into sequence enrichment and targeted resequencing applications.

The study, published in Nature Biotechnology, found that RainDance Technologies' microdroplet-based PCR technology was more scalable than standard PCR for sequence enrichment, with comparable sensitivity and accuracy.

Newsweek discusses the privacy issues raised by digital medicine.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.